



MEDIA RELEASE: Sydney, Australia. Thursday 6 February, 2014.

MANUFACTURING AND PRODUCT SUPPLY UNDERWAY AT NEW PHEBRA PLANT

Australian pharmaceutical firm Phebra has announced that manufacturing and product supply from its new sterile manufacturing plant at Lane Cove West is well underway.

Chief Executive Officer, Dr Mal Eutick, said Phebra had successfully relocated from its previous site at Burns Bay Road, Lane Cove, which has now been closed and the site sold for the development of a significant number of residential units.

Dr Eutick said the new plant, situated at Orion Road, allowed Phebra to greatly enhance its current capacity to manufacture critical medicines for the local Australian and New Zealand markets and wider export markets.

“We’re pleased to advise that the new plant is fully operational and is supplying medicines,” Dr Eutick said today.

“The facility will deliver extra production capacity for Phebra to manufacture our wide range of critical medicines, as well as expanding our capability to conduct all-important development programs now and into the future.”

Dr Eutick said Phebra is committed to providing skills development and employment opportunities to assist in local R&D of commercial products for both local and export markets.

ABOUT PHEBRA

Phebra is an Australian specialty pharmaceutical company that develops, manufactures and markets critical medicines in Australia, New Zealand, Asia, Canada and parts of Europe.

The company’s critical medicines cover a range of pharmaceuticals in important disease areas such as cystic fibrosis, antidotes, diagnostics, oncology and pain.

At Phebra, we create critical medicines that save and improve lives.

Media contact:
Richard Lenarduzzi at The Premier Communications Group
0411 254 390
info@premiercomms.com.au